Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Should You Invest in This Under-the-Radar Weight Loss Stock?
09:53am, Sunday, 30'th Nov 2025
Vanda reported strong phase 2 results for a candidate that could be used with GLP-1 drugs. However, this medicine's potential target market appears small and may shrink further.
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
11:10am, Friday, 28'th Nov 2025
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
07:00am, Friday, 28'th Nov 2025
FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies Separately, FDA recently issued labeling commen
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality
03:31am, Friday, 21'st Nov 2025
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has dr
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
11:11am, Wednesday, 19'th Nov 2025
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients
10:49am, Tuesday, 18'th Nov 2025
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induc
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
06:37pm, Monday, 17'th Nov 2025
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON , Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leadi
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
05:00pm, Wednesday, 05'th Nov 2025
WASHINGTON , Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City
Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript
10:16pm, Wednesday, 29'th Oct 2025
Vanda Pharmaceuticals Inc. ( VNDA ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Kevin Moran - Senior VP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & C
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates
06:21pm, Wednesday, 29'th Oct 2025
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.09 per share a year ago.
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 29'th Oct 2025
Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target ac
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
04:30pm, Wednesday, 22'nd Oct 2025
Conference Call and Webcast to Follow WASHINGTON , Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on
Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For photo
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
05:02pm, Wednesday, 01'st Oct 2025
WASHINGTON , Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration (
WASHINGTON , Sept. 25, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves s
